Evidence map›Paper›PMID 36276286›Full record

ArticleJournal of oncology2022

Lu-Lu Wang, Xue Tang, Guichi Zhou, Shilin Liu, Ying Wang, Fen Chen, Tonghui Li, Feiqiu Wen, Sixi Liu, Huirong Mai

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Aberrant stem cell and developmental programs in pediatric leukemia.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lu-Lu WangDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.ORCID https://orcid.org/0000-0001-8339-6554
Xue TangDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Guichi ZhouDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Shilin LiuDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Ying WangDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Fen ChenDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Tonghui LiDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Feiqiu WenDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Sixi LiuDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.
Huirong MaiDepartment of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen 518038, China.ORCID https://orcid.org/0000-0002-8970-9221
Shenzhen Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of over 90% of infant acute lymphoblastic leukemia (ALL) remains poor because of harboring the mixed-lineage leukemia gene (

Identifiers

PMID36276286
PMCPMC9586771
OpenAlexW4306252534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.